Eli Lilly & Co. said Tuesday that a phase 3 safety and efficacy study of Taltz for the treatment of ankylosing spondylitis (AS) met the primary and all key secondary endpoints. Eli Lilly said it plans to submit data for regulatory approval, pending additional data from the ongoing Taltz development program. Taltz is currently approved for treatment of psoriatic arthritis in adults, and to treat adults with moderate-to-severs plaque psoriasis. Eli Lilly’s stock, which is still inactive in premarket trade, has shed 8.0% over the past three months, while the SPDR S&P Pharmaceuticals ETF has gained 1.1% and the S&P 500 has tacked on 2.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News